Related Experiment Video
Updated: Mar 31, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
32.7K
Roflumilast for asthma: Efficacy findings in placebo-controlled studies
E O Meltzer1, P Chervinsky2, W Busse3
1Department of Pediatrics, Division of Allergy and Immunology, University of California, San Diego, CA, USA.
Pulmonary Pharmacology & Therapeutics
|October 27, 2015
Summary
Roflumilast shows potential as an asthma treatment, improving lung function (FEV1) in clinical trials. Combination therapy with inhaled corticosteroids (ICS) demonstrated additional benefits, warranting further investigation for asthma management.
Area of Science:
- Pharmacology and Therapeutics
- Respiratory Medicine
- Clinical Trials
Background:
- The therapeutic role of roflumilast for asthma remains incompletely defined.
- Placebo-controlled trials were conducted to assess roflumilast's safety and efficacy in asthma patients.
Purpose of the Study:
- To evaluate the efficacy of roflumilast through nine randomized, placebo-controlled clinical studies.
- Assessed both monotherapy and combination therapy approaches in Phase II and III trials.
Main Methods:
- Data from 4873 patients (12-70 years) across 9 international studies (4-24 weeks).
- Roflumilast (125, 250, 500 μg) or placebo, with some receiving add-on therapy to inhaled corticosteroids (ICS).
- Primary endpoint: Forced Expiratory Volume in 1 second (FEV1) improvement; secondary: asthma symptoms and exacerbations.
Main Results:
- Roflumilast consistently improved FEV1 compared to placebo, achieving statistical significance in three studies.
- Add-on therapy with 500 μg roflumilast to beclomethasone dipropionate (BDP) showed statistically significant FEV1 improvement over placebo plus BDP.
Conclusions:
- Roflumilast demonstrates potential as an anti-inflammatory asthma therapy.
- Combination with ICS offers additional benefits, suggesting a role in comprehensive asthma treatment strategies.
- Further research is recommended to explore roflumilast's combined therapeutic effects in asthma.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.3K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
2.3K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.3K
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K
01:30Asthma-IV: Diagnostic and Management
3.3K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.3K
01:26Asthma-II: Pathophysiology and Classification
4.9K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.9K
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.1K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.1K